Cortexin
Also known as: Korteksin, Cortexin polypeptide complex, cerebral cortex polypeptide complex
Polypeptide neuroprotective complex (lyophilized extraction of animal cortex; contains neuropeptides, amino acids, and trace elements)
What it is
Cortexin is a neuropeptide preparation used in Russia and Eastern Europe for stroke recovery, cognitive impairment, and depression. It is derived from brain tissue and is thought to support neurological repair and function. Not FDA-approved; approved and widely used in Russia; most clinical evidence comes from Russian trials.
The scientific side
Cortexin is described as a lyophilized extraction of animal (calf/cattle) cerebral cortex containing neuropeptides, amino acids, and trace elements, with nucleoprotein complexes that may also retain chromatin elements with DNA fragments. Its proposed molecular mechanisms include normalization of glutamatergic (including NMDA receptor-mediated) transmission, antioxidant and anti-inflammatory action, restoration of the blood-brain barrier, and modulation of the cytokine profile. Epigenetic mechanisms have been proposed whereby short peptide derivatives (EDR and DS) bind histone H1.3, potentially altering chromatin structure at gene loci such as Fkbp1b, which encodes a protein regulating calcium release from neuronal organelles. Additional mechanisms include stimulation of neuroprotection, neuroplasticity, and neurorepair processes. Biomarkers reported to reflect Cortexin activity include reductions in NR2-peptide concentration (neurotoxicity marker), enhancement of antioxidant (superoxide dismutase) activity, and modulation of cytokine profile.
Class: Polypeptide neuroprotective complex (lyophilized extraction of animal cortex; contains neuropeptides, amino acids, and trace elements)
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Acute ischemic stroke — neurological and cognitive recovery Human RCT
- Multicenter RCT (n=490): Cortexin 10 mg IV and 10 mg IM (2 times/day, two 10-day courses) showed comparable efficacy; 93.64% vs 86.50% reached mRS 0-2 at day 90. NIHSS decreased by ~3.93 and ~3.72, respectively. Comparable safety profiles. PMID 41524350 Fedin AI et al. Zhurnal nevrologii i psikhiatrii (2025)
- Multicenter double-blind placebo-controlled RCT (n=272): Cortexin 10 mg three times daily IM for two 10-day courses showed high efficacy and safety; best outcomes in the two-course group, confirmed by pharmacoeconomic analysis. PMID 24874316 Aliferova VM et al. Zhurnal nevrologii i psikhiatrii (2014)
- Most complete regression of neurological deficit in acute hemispheric ischemic stroke observed with Cortexin 30 mg/day (10+10+10 mg IM) in two 10-day courses compared to lower doses or fewer courses. PMID 30132453 Belova LA et al. Zhurnal nevrologii i psikhiatrii (2018)
- Repeated course of Cortexin 20 mg/day IM led to more complete regression of neurological deficit in acute and recovery period of ischemic stroke compared to single course or basic therapy alone. PMID 27845314 Belova LA et al. Zhurnal nevrologii i psikhiatrii (2016)
- RCT (n=40): Cortexin 10 mg per 2 ml 0.9% NaCl IM daily for 10 days in early recovery period of ischemic stroke. Cellex was more effective than Cortexin on NIHSS and MMSE dynamics; no significant difference in RMI and FAB. PMID 33449527 Khabirov FA et al. Zhurnal nevrologii i psikhiatrii (2020)
- Chronic cerebral ischemia — cognitive and neurological improvement Human observational
- Multicenter RCT (n=189): Cortexin 10 mg and 20 mg IM for 10 days (repeated at 6 months) showed dose-dependent effects on neurological disorders, asthenia, and sleep; antioxidant effect confirmed at both doses; safety and tolerability confirmed. PMID 30335070 Fedin AI et al. Zhurnal nevrologii i psikhiatrii (2018)
- Multicenter observational study (n=801): Complex therapy with Cortexin 10 mg/day for 10 days plus Neuromexol showed significant reduction in cognitive impairment severity; 2-fold decrease in NSE; reduction in antibodies to NR2; effective and safe. PMID 38147380 Mashin VV et al. Zhurnal nevrologii i psikhiatrii (2023)
- Multicenter observational program (n=309): Cortexin 10 mg/day for 10 days plus recognan (citicoline) showed high efficacy in vascular cognitive disorders. PMID 30874524 Belova LA et al. Zhurnal nevrologii i psikhiatrii (2019)
- Multicenter observational program 'KORMEN' (n=495): Significant positive effect of Cortexin (alone or with memantine) on cognitive scales in CCI patients; addition of memantinol improved outcomes in severe cognitive impairment. PMID 29460902 Fedin AI et al. Zhurnal nevrologii i psikhiatrii (2018)
- Post-COVID cognitive impairment and neurological disorders Human observational
- Study (n=109): Cortexin 10 mg IM continuously for 20 days (repeated at 3 and 6 months) produced statistically significant improvements in concentration, executive functions, and auditory-verbal memory; no adverse events. PMID 39113450 Melnik EA. Zhurnal nevrologii i psikhiatrii (2024)
- Multicenter program (n=979): Cortexin 10 mg and 20 mg IM for 10 days effective for cognitive and asthenic postcovid disorders; anxiolytic/antidepressant activity more pronounced at 20 mg. PMID 35175707 Putilina MV et al. Zhurnal nevrologii i psikhiatrii (2022)
- Neurological complications of type 2 diabetes mellitus (cognitive impairment, anxiety-depression, diabetic polyneuropathy) Human RCT
- Multicenter RCT (n=110): Ten doses of Cortexin 10 mg IM added to comprehensive treatment produced superior regression of cognitive symptoms (6.0x vs 1.7x), reduction of HADS anxiety (1.6x) and depression (1.7x), and reduction of neuropathy scores vs control. High safety profile; only 5 AEs total across both groups, non PMID 42133422 DIACORT trial. Zhurnal nevrologii i psikhiatrii (2026)
- Depressive disorder (adjunctive therapy) Human observational
- Study (n=98): Cortexin 10 mg IM once daily for 10 days as add-on to antidepressants produced significant reduction in MADRS, improvement in SASS (quality of life), and fewer side effects vs antidepressant monotherapy (p=0.001). PMID 41782536 Schastnyy ED. Zhurnal nevrologii i psikhiatrii (2026)
- Alcoholic encephalopathy and alcohol polyneuropathy Human RCT
- Study (n=40): Cortexin 10 mg or 20 mg IM for 10 days in alcoholic encephalopathy produced significant improvements in MMSE (27.3→28.9), FAB (15.5→17.1), and Schulte tables (97.5s→84.5s) in both dose groups. PMID 42360215 Masaleva IO, Ivenkov MP. Zhurnal nevrologii i psikhiatrii (2026)
- Open RCT: Cortexin 10 mg/day IM for 10 days in chronic alcohol encephalopathy and polyneuropathy showed positive effects on clinical symptoms, EEG, and ENMG; well-tolerated, no side effects observed. PMID 20517210 Solov'ev AG, Elistratova TV. Zhurnal nevrologii i psikhiatrii (2010)
- Pediatric neuropsychiatric pathology (hypoxic-ischemic CNS injury, perinatal lesions) Human RCT
- RCT (n=323 children, age 7 days to 1 year): Two courses of Cortexin with 3-month interval significantly reduced frequency and severity of myotonic and hypertensive-hydrocephalic syndromes vs controls; 73.4% and 71.3% showed increased bioelectric activity (10-12 Hz). PMID 39731376 Degtyareva VG et al. Zhurnal nevrologii i psikhiatrii (2024)
- Post-stroke aphasia and speech disorders Human observational
- Study (n=71): Cortexin 10 mg twice daily IM combined with Aphasia.No app led to statistically significant improvements in speech, writing, and reading scores compared to baseline and comparison group. PMID 39690562 Kuznetsova EB et al. Zhurnal nevrologii i psikhiatrii (2024)
- Post-stroke cognitive impairment in young patients Human observational
- Prospective observational study (n=30, ages 18-45): Cortexin treatment produced MoCA improvement from 25.1 to 28.4 (significant at end of second course); quality of life (SF-36) significantly improved at visit 4 and maintained. PMID 39269301 Shchepankevich LA et al. Zhurnal nevrologii i psikhiatrii (2024)
- Cerebral palsy — motor, cognitive, and speech disorders Mixed
- Review article: High efficacy of Cortexin described for motor, cognitive, and autonomic disorders in children with perinatal CNS lesions and cerebral palsy, attributed to multimodal action (neuropreparation, neuroprotection, neuroplasticity stimulation). PMID 38261281 Nemkova SA, Boldyrev VG. Zhurnal nevrologii i psikhiatrii (2024)
- Controlled clinical trial (n=78, ages 2-7): Combined MCRT and Cortexin (10 injections per session, after 1st and 3rd MCRT sessions) showed high efficacy in recovery of speech functions in cerebral palsy vs MCRT alone. PMID 21946134 Ukhanova TA et al. Zhurnal nevrologii i psikhiatrii (2011)
- Pediatric ADHD, dyslexia, memory disorders, speech delay Human observational
- Multicenter study (n=635, ages 3-7): Standard course of 10 IM injections of Cortexin showed reliable improvement in cognitive impairment across ADHD, speech delay, perinatal CNS lesions, and asthenic/neurotic syndrome groups; best response in ADHD ages 3-4. PMID 29652302 Zykov VP et al. Zhurnal nevrologii i psikhiatrii (2018)
- Study (n=60, ages 8-11): Cortexin treatment in dyslexia showed improvement in 73.3% vs 60.0% with encephabol; significant neurophysiological changes on EEG indicating activation of brain regulatory systems. PMID 33728849 Chutko LS et al. Zhurnal nevrologii i psikhiatrii (2021)
- Controlled clinical trial (n=60, ages 7-12): Cortexin improved memory disorders in 86.7% of children vs 63.3% with encephabol, confirmed by neuropsychological and neurophysiological data. PMID 22027605 Chutko LS et al. Zhurnal nevrologii i psikhiatrii (2011)
- RCT (n=54, ages 3-4): Cortexin once daily IM for 10 days in developmental dysphasia produced significant improvement in expressive/impressive language and attention to speech; active vocabulary increased 2.3x, articulated phrases 3.6x; protracted effect observed. PMID 31851172 Zavadenko NN et al. Zhurnal nevrologii i psikhiatrii (2019)
- Traumatic brain injury consequences Human observational
- Review: High efficiency of Cortexin in correcting asthenic, cognitive, emotional, and liquorodynamic disorders in the long-term period of TBI described. PMID 36946393 Solovieva EY et al. Zhurnal nevrologii i psikhiatrii (2023)
- Epilepsy in children and adolescents (cognitive and behavioral comorbidities) Human observational
- Study (n=86, ages 3-17): Cortexin used alongside antiepileptic drugs; cognitive improvement in 65% of patients; no seizure aggravation in 95%; improvement of electrophysiological parameters observed. PMID 33834730 Kalmykova GV et al. Zhurnal nevrologii i psikhiatrii (2021)
- Post-stroke epilepsy Human observational
- Study (n=46): Cortexin 10 mg IM for 15 days as add-on to depakine-chrono significantly enhanced clinical effects and produced positive EEG changes in post-stroke epilepsy. PMID 20873481 Gafurov BG, Gafurov ShB. Zhurnal nevrologii i psikhiatrii (2010)
- Organic emotionally labile (asthenic) disorders — neuroendocrine effects Human RCT
- RCT: Addition of Cortexin to standard therapy normalized blood concentrations of cortisol, dehydroepiandrosterone sulphate, and thyroid hormones; clinical improvement associated with recovery of homeostatic systems. PMID 23667876 Levchuk LA et al. Bulletin of experimental biology and medicine (2013)
- Obstructive sleep apnea — cognitive protection Human observational
- Review/observational: Cortexin with multimodal mechanism proposed to minimize negative impact of OSA on cognitive health; no primary efficacy data presented. PMID 37655408 Khoreva MA et al. Zhurnal nevrologii i psikhiatrii (2023)
- Animal model: perinatal hypoxic-ischemic brain injury Animal studies only
- Rat model (7-day-old rats, carotid ligation + hypoxia): Cortexin 1 mg/kg IP daily for 10 days showed transient improvement in EMG spectral structure on day 10 but effect not sustained at day 30. Administration to intact infant rats caused disturbances of vagosympathetic balance, heart rhythm, and respiration — suggesti PMID 30695499 Kuznetsov SV, Kuznetsova NN. Zhurnal evoliutsionnoi biokhimii i fiziologii (2016)
Protocol
No community protocol on record. In clinical studies, Cortexin was dosed at 10 mg or 20 mg Intramuscular injection (PMID 42360215).
All studies (35)
- PMID 20517210 Human RCT
Alcoholic encephalopathy and alcohol polyneuropathy - PMID 23667876 Human RCT
Organic emotionally labile (asthenic) disorders — neuroendocrine effects - PMID 24874316 Human RCT
Acute ischemic stroke — neurological and cognitive recovery - PMID 27845314 Human RCT
Acute ischemic stroke — neurological and cognitive recovery - PMID 30132453 Human RCT
Acute ischemic stroke — neurological and cognitive recovery - PMID 33449527 Human RCT
Acute ischemic stroke — neurological and cognitive recovery - PMID 39731376 Human RCT
Pediatric neuropsychiatric pathology (hypoxic-ischemic CNS injury, perinatal lesions) - PMID 41524350 Human RCT
Acute ischemic stroke — neurological and cognitive recovery - PMID 42133422 Human RCT
Neurological complications of type 2 diabetes mellitus (cognitive impairment, anxiety-depression, di - PMID 42360215 Human RCT
Alcoholic encephalopathy and alcohol polyneuropathy - PMID 20873481 Human observational
Post-stroke epilepsy - PMID 22027605 Human observational
Pediatric ADHD, dyslexia, memory disorders, speech delay - PMID 29460902 Human observational
Chronic cerebral ischemia — cognitive and neurological improvement - PMID 29652302 Human observational
Pediatric ADHD, dyslexia, memory disorders, speech delay - PMID 30335070 Human observational
Chronic cerebral ischemia — cognitive and neurological improvement - PMID 30874524 Human observational
Chronic cerebral ischemia — cognitive and neurological improvement - PMID 31851172 Human observational
Pediatric ADHD, dyslexia, memory disorders, speech delay - PMID 33728849 Human observational
Pediatric ADHD, dyslexia, memory disorders, speech delay - PMID 33834730 Human observational
Epilepsy in children and adolescents (cognitive and behavioral comorbidities) - PMID 35175707 Human observational
Post-COVID cognitive impairment and neurological disorders - PMID 36946393 Human observational
Traumatic brain injury consequences - PMID 37655408 Human observational
Obstructive sleep apnea — cognitive protection - PMID 38147380 Human observational
Chronic cerebral ischemia — cognitive and neurological improvement - PMID 39113450 Human observational
Post-COVID cognitive impairment and neurological disorders - PMID 39269301 Human observational
Post-stroke cognitive impairment in young patients - PMID 39690562 Human observational
Post-stroke aphasia and speech disorders - PMID 41782536 Human observational
Depressive disorder (adjunctive therapy) - PMID 21946134 Mixed
Cerebral palsy — motor, cognitive, and speech disorders - PMID 38261281 Mixed
Cerebral palsy — motor, cognitive, and speech disorders - PMID 25403301
10 mg/day Not explicitly stated (Cortexin; IM implied by context) (human) - PMID 27459764
10 mg IM twice daily (morning and afternoon) Intramuscular injection (human) - PMID 27905386
20 mg (10+10) IM Intramuscular injection (human) - PMID 30695499 Animal studies only
Animal model: perinatal hypoxic-ischemic brain injury - PMID 31099784
- PMID 31626220
20 mg per day Intramuscular injection (human)